August 07, 2023

To, The Manager **Dept of Corporate Services BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001

Dear Sir/Madam,

Subject

: Outcome of the Board Meeting

Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulation, 2015

Scrip

: 511509

With reference to the above cited subject and our letter dated July 24, 2023, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Monday, August 07, 2023, inter-alia, transacted the following business:

1. Approved the Un-Audited Standalone & Consolidated Financial Statements of the Company for the first quarter ended June 30, 2023.

The meeting commenced at 07.30 p.m. and concluded at 08.00 p.m.

This is for your information and records.

Thanking You,

Yours faithfully

For Vivo Bio Tech Limited

Jyotika Aasat

Company Secretary

Encl as above

Vivo Bio Tech Limited 03rd Floor, Ilyas Mohammed Khan Estate, 8-2-672,5&6, Road No.1, Banjara Hills, Hyderabad-500034 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

			- 00 010111	2000	
	UN-AUDITED STANDALONE FINANCIAL RESULIS FOR THE QUARTER ENDED SU JUNE 2023	S FOR THE QUAR	I EK ENDED 30 JC	JINE 2023	Rs. in Lacs
			QUARTER ENDED		YEAR ENDED
S.No.	PARTICULARS	30.06.2023	31.03.2023	30.06.2022	31.03.2023
		Un-Audited	Refer Note #2	Un-Audited	Audited
-	Revenue from operations	1,158.21	1,440.01	1,126.33	5,162.29
=	Other Income	-	2.05	0.00	3.59
≡	Total Income	1,158.21	1,442.06	1,126.42	5,165.79
≥	Expenses				
	a) Increase/(decrease) in stock in trade and WIP	91.02	34.96	-52.83	183.34
	b) Consumption of Raw materials	-			
	c) Purchase of traded goods	84.38		134.85	
	d) Employees Cost	290.55		312.98	1,315.01
	e) Depreciation and amortisation	228.52		233.47	926.57
	f) Finance Cost	194.72	201.43	176.26	765.13
	g)Administrative Expenditure	232.2	268.75	253.05	1,021.54
	Total	1,121.39	1,156.94	1,057.79	4,705.24
>	Profit Before Tax & Exceptional Items (III-IV)	36.82	285.11	68.63	460.54
	Exceptional Item		-	-	1
	Prior Period Items	1	1	1	
>	Profit Before Tax	36.82	285.11	68.63	460.54
5	Tax Expense				
	a. Current Tax	17.13	7		
	b. Deffered tax	-6.06			
	Total Tax Expense	11.07			
	VIII Net Profit After Tax (V-VI)	25.75	203.75	31.61	263.40
×	Other Comprehensive Income				
	a. Items that will be reclassified to profit or loss (Net of Tax)	1	1		
×	Total other Comprehensive Income(VII+VIII+IX)	25.75	203.75		
=	Paid Up Share Capital (Face value of Rs.10/-" (In lakh Units)	1,490.35	1,490.35	1,487.65	1,490.35
₹	_				
	1)Basic	0.17			
	2)Diluted	0.17	1.3/	0.22	1.//
Plac	Place: Hyderabad	\		For Vivo Bio Tech Limited	ech Limited
Date	Date: August 07, 2023	TB TB	1 100	Z	}
		ON	O Hyderabad 5	Kalyan Ram Mangipudi	angipudi
			1	Whole Time Director	rector

Vivo Bio Tech Limited 03rd Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6, Road No.1, Banjara Hills, Hyderatad-500034 E-mail:investors@vivobio.com CIP: L65993TG1987PLC007163

Vivo Bio Tech Ltd. Your Drug Discovery Partner

UN-AUCITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2023

					Rs. in Lacs
S S	SaviliJILave		QUARTER ENDED		YEAR ENDED
5	ANTICOLANS	30.06.2023	31.03.2023	30.06.2022	31.03.2023
		Un-Audited	Refer Note #2	Un-Audited	Audited
-	Revenue from operations	1,158.21	1,475.82	1,126.33	5,223.02
=	Other Income		2.05	0.00	
Ξ	Total Income	1,158.21	1.477.87	1.126.42	5.22
<u>\</u>	Expenses				1000
	a) Increase/(decrease in stock in trade and WIP	91.02	34.96	-52.83	183 94
	b) Consumption of Raw materials				
	c) Purchase of tradec goods	84.38	92.05	134.85	493.05
	d) Employees Cost	302.04	345.17	312.98	1.352.35
	e) Depreciation and amortisation	228.52	226.03	233.47	925.57
	f) Finance Cost	194.72	201.43	176.26	765.13
	g)Administrative Exp=nditure	232.25	290.56	253.05	1.043.49
	_otal	1,132.90	1,190.19	1,057.79	4,764.52
>	Profit Before Tax & Excertional Item (III-IV)	25.31	287.67	68.63	462.08
	Expceptional Item			,	
	Prior Period Items		1		,
IN	Profit Before Tax	25.31	287.67	68.63	462.08
IIA	Tax Expense				
	a. Current Tax	17.13	73.52	11.46	103.05
	b. Deffered tax	90.9-	7.84	25.57	94.13
	Total Tax Expense	11.07	81.35	37.03	197.17
	VIII Net Profit After Tax (V-VI)	14.24	206.32	31.60	264.91
×	Minority Interest		٠		
×	Other Comprehensive Income				
	a.Items that will be reclasified to profit or loss (Net of Tax)		,	,	
×	Total other Comprehenive Income(VII+VIII+IX)	14.24	206.32	31.60	264.91
₹	Paid Up Share Capital (F≡e value of Rs.10/-) (In lakh Units)	1,490.35	1,490.35	1,487.65	1,490.35
≡ ×	Earnings per equity shan:				
	1)Basic	0.10	1.38	0.22	1.78
	2)Diluted	0.10	1.38	0.22	1.78
Place: Hyderabad Date: August 07, 2	Place: Hyderabad Date: August 07, 2023		OTECK	For Vivo Bio Tech Limited	imited
		ON	(Hyderabad) 区	Kalyan Ram Mangipudi	ipno
			1	Whole Time Director	-
				MA: 02012380	


Notes:

- 1. The above Un-Audited Financial Results for the 01st Quarter June 30, 2023, were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 07, 2023.
- 2. The figures for the quarter ended March 31, 2023 are the balancing figure between the audited figures of the full financial year and the published year-to-date figures upto the 3rd quarter of respective financial years which were subject to Limited Review by the Statutory Auditor of the Company.
- 3. The Un-Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 4. The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakanti Consulting Services Private Limited).
- 5. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
- 6. The above financial results are available on the stock exchange website www.bseindia.com and company's website www.vivobio.com.
- 7. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

Date: August 07, 2023 Place: Hyderabad For Vivo Bio Tech Limited

Kalyan Ram Mangipudi Whole Time Director

DIN: 02012580



Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

FAX : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


Review report to The Board of Directors Vivo Biotech Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Vivo Biotech Limited** (the "Company") for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





Tel.

: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

FAX

: (91-40) 2339 2474

: pmurali.co@gmail.com

info@pmurali.com Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.Murali & Co, Chartered Accountants

FRN: 007257S


M V Joshi

Partner

M.No. 024784

UDIN: 23024784BGVPSV3361

Place: Hyderabad Date: 07-08-2023



Tel.

FAX

E-mail

: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470 : (91-40) 2339 2474

: pmurali.co@gmail.com

info@pmurali.com Website: www.pmurali.com


Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to The board of directors Vivo Bio Tech Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of Vivo Bio Tech Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

FAX : (91-40) 2339 2474 : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Vivo Bio Labs Private Limited

2. Vivo Bio Discovery Services Private Limited

3. Surlogic Life Consultancy Private Limited

Vivo Bio Consulting Services Private Limited (Formerly known as 4. Donakanti Consultancy Services Private Limited)

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.Murali & Co. Chartered Accountants

FRN: 007257S

Partner

M.No. 024784

UDIN: 23024784BGVPSW6139

Place: Hyderabad Date: 07-08-2023